ZOGENIX, INC. - FORM 10-K - EX-21.1 - March 2, 2020

Attached files

file filename
EX-10.7 - EX-10.7 - ZOGENIX, INC.zgnx-20191231x10kxex106.htm
EX-10.22 - EX-10.22 - ZOGENIX, INC.zgnx-12312019ex1023.htm
EX-31.1 - EX-31.1 - ZOGENIX, INC.zgnx-12312019xex311.htm
EX-31.2 - EX-31.2 - ZOGENIX, INC.zgnx-12312019xex312.htm
EX-32.2 - EX-32.2 - ZOGENIX, INC.zgnx-12312019xex322.htm
10-K - 10-K - ZOGENIX, INC.zgnx-20191231.htm
EX-32.1 - EX-32.1 - ZOGENIX, INC.zgnx-12312019xex321.htm
EX-4.3 - EX-4.3 - ZOGENIX, INC.zgnx-12312019xex43.htm
EX-23.1 - EX-23.1 - ZOGENIX, INC.zgnx-12312019xex231.htm
Exhibit 21.1
SUBSIDIARIES OF ZOGENIX, INC.

All subsidiaries are wholly-owned, directly or indirectly, by Zogenix, Inc.


Name of SubsidiaryJurisdiction of
Formation
Modis Therapeutics, Inc.Delaware
Name of Non-U.S. SubsidiaryJurisdiction of
Formation
Zogenix Europe LimitedUnited Kingdom
Zogenix GmbHGermany
Zogenix International LimitedUnited Kingdom
Zogenix ROI LimitedIreland
Zogenix S.r.l.Italy


ZOGENIX, INC. Reports